CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
← catalyst calendarSponsored by Caribou Biosciences, Inc. (industry) · CRBU — their whole pipeline →.
Phase
Phase 1
Status
Unknown status
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
72estimated
Sites
38
Countries
Australia, Israel, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-05-26 | actual | When the study began enrolling |
| Primary completion | Aug 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2020-11-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Lymphoma, Non-Hodgkin
- Relapsed Non Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Non Hodgkin Lymphoma
- Lymphoma
- B Cell Lymphoma
- B Cell Non-Hodgkin's Lymphoma
Interventions
- Genetic: CB-010
- Drug: Cyclophosphamide
- Drug: Fludarabine
Primary outcomes
what the primary-completion date above is the date OFPrimary outcome measures number of patients with dose-limiting toxicities (Part A).
measured 28 days following CB-010 infusion
Primary outcome evaluates tumor response (Part B)
measured Up to 12 months
Permalink · CRBU's whole pipeline · Catalyst calendar · Every registered study · What changed